Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2B study of daclatasvir with peginterferon alfa-2a and ribavirin in chronic hepatitis C genotype 1 prior null/partial responders
2010-019378-34Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of daclatasvir in hepatitis C virus infection (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Rapid virologic response (RVR) at Week 4. Started Jul 2010; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-019378-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019378-34.